05:17 , Mar 31, 2017 |  BC Week In Review  |  Financial News

Nosopharm completes venture financing

Antibiotic company Nosopharm S.A.S. (Nimes, France) raised €2.4 million ($2.6 million) in a venture round from new investors Auriga Partners, Kreaxi and Alto Invest and existing investors on March 28. Nosopharm S.A.S. , Nimes, France ...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Financial News

GamaMabs Pharma completes venture financing

GamaMabs Pharma S.A. , Toulouse, France   Business: Cancer, Antibodies   Date completed: 2015-12-15   Type: Venture financing   Raised: EUR15 million ($16.4 million)   Investors: BioDiscovery 4; InnoBio Fund; IRDINov; Alto Invest; iXO Private...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Financial News

Novacyt completes private placement

Novacyt S.A. (Euronext:ALNOV), Velizy-Villacoublay, France   Business: Supply/Service   Date completed: 2015-07-23   Type: Private placement   Raised: EUR2 million ($2.2 million)   Shares: 399,500   Price: EUR5   Shares after offering: 7.1 million  ...
07:00 , Jun 22, 2015 |  BioCentury  |  Emerging Company Profile

Singling out ovarian cancer

GamaMabs Pharma S.A. is developing a first-in-class mAb that has the potential to treat chemotherapy-resistant subtypes of ovarian cancer by activating phagocytosis in tumor-infiltrating immune cells and tethering them to tumor cells expressing a cancer-specific...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Financial News

Novacyt completes private placement

Novacyt S.A. (Euronext:ALNOV), Velizy-Villacoublay, France   Business: Supply/Service   Date completed: 2015-04-13   Type: Private placement   Raised: EUR2.2 million ($2.3 million)   Shares: 442,000   Shares after offering: 6.7 million   Investors: Alto Invest;...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Financial News

Novacyt completes private placement

Novacyt S.A. (Euronext:ALNOV), Velizy-Villacoublay, France   Business: Supply/Service   Date completed: 2014-12-09   Type: Private placement   Raised: €3.1 million ($3.8 million)   Shares: 744,004   Price: Not disclosed   Shares after offering: 6.3 million...
08:00 , Feb 6, 2012 |  BioCentury  |  Finance

DBV readies IPO

French allergy play DBV Technologies is the second company this year to announce plans for an IPO on Euronext Paris. DBV has filed its "document de base," the French equivalent of a preliminary prospectus. Once...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Financial News

DBV completes venture financing

DBV Technologies , Paris, France   Business: Inflammation, Diagnostic   Date completed: 1/5/11   Type: Venture financing   Raised: $25.5 million   Investors: InnoBio Fund; Lund-beckfond Ventures; Shire; Alto Invest; Sofinnova Partners; ALK Abello A/S...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Peanut Epicure

Peanut epicure With €9.4 million ($25.5 million) in hand from a series C round, DBV Technologies believes it has enough cash to complete a pivotal study of allergy candidate Viaskin Peanut , a patch that...
01:29 , Jan 6, 2011 |  BC Extra  |  Financial News

France's DBV raises $25.5 million

DBV Technologies (Paris, France) raised $25.5 million in a series C round led by new investors InnoBio Fund and Lundbeckfond Ventures. New investors Shire plc (LSE:SHP; NASDAQ:SHPGY) and Alto Invest and existing investors Sofinnova Partners...